8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37)

8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37)

Quick Answer: Minnesota pharmacists may prescribe under Minn. Stat. §151.37: self-administered hormonal contraceptives (subd. 14), FDA-approved nicotine replacement medications (subd. 15), opiate antagonists for acute opiate overdose (subd. 16), and drugs to prevent HIV acquisition (subd. 17). Each authority requires Board standardized protocol use, specific training, patient counseling/fact sheet, and prohibits delegating the prescribing decision (an intern may prepare the Rx, but an authorized pharmacist must review, approve, and sign). These lanes are not general independent medical practice.

This section is high-yield for Area 2. Exam writers love mixing §151.37 prescribing with CPA therapy management and with opioid-antagonist public-access rules taught later. Keep the subdivision numbers straight.

Five Limited Prescribing Lanes at a Glance

§151.01, subd. 27 incorporates these authorities in the practice definition: clause (12) (contraceptives, NRT, acute-overdose antagonists) and clauses (14)–(15) (HIV-prevention prescribing/dispensing/administering and related labs—note effective-date history in statute notes for those clauses).

§151.01, subd. 42 defines self-administered hormonal contraceptive: a drug composed of a combination of hormones, FDA-approved to prevent pregnancy, administered by the user.

Common Rules Across Subds. 14–17

Subdivision 18 uses a distinct OUD-treatment framework described below; do not import every standardized-protocol or fact-sheet detail from subds. 14–17 into subd. 18.

Although product categories differ, the architecture is parallel:

1. Board develops a standardized protocol (with consultation duties involving medical/nursing boards, commissioner of health, and professional associations as each subdivision requires).
2. Training must be completed before the pharmacist is authorized to prescribe under that subdivision—typically a program from a college of pharmacy, an ACPE-accredited CE provider, or a Board-approved program, plus Board-specified CE to maintain authorization.
3. Follow the protocol before prescribing; prescribe/dispense only when appropriate under the protocol.
4. Counsel the patient and provide a fact sheet covering indications/contraindications (or contraception-specific content for subd. 14), proper use, need for medical follow-up, and information aligned with counseling content under Rule 6800.0910, subp. 2 as the statute references.
5. Provide a written record of what the pharmacist prescribed (expressly required in subds. 14–16; HIV subdivision emphasizes counseling/fact sheet before dispensing the pharmacist-prescribed drug).
6. No delegation of prescribing to any other person. A pharmacist intern registered under §151.101 may prepare the prescription, but an authorized pharmacist must review, approve, and sign before processing/dispensing.
7. Nothing in these subdivisions prohibits protocol/CPA therapy management under §151.01, subd. 27.

Subd. 14 — Self-Administered Hormonal Contraceptives

Protocol content minimums

The Board protocol must, at a minimum, include:

1. Patient completion of a self-screening tool based on current U.S. Medical Eligibility Criteria for Contraceptive Use (CDC MEC) to identify risk factors
2. Pharmacist review of the screening tool with the patient
3. Other assessments before prescribing
4. Situations when pharmacist prescribing is contraindicated
5. Situations requiring referral to the patient’s primary care provider or, if none, a nearby clinic or hospital
6. Additional Board-specified requirements and prohibitions

Who may receive a pharmacist-prescribed product

After following the protocol, the pharmacist may prescribe if the patient is:

• 18 years of age or older; or
• Under 18 only if the patient has previously been prescribed a self-administered hormonal contraceptive by a licensed physician, physician assistant, or advanced practice registered nurse

Counseling, record, and refill gate

• Counsel on use; provide fact sheet (contraindications, method of use, need for medical follow-up, and Rule 6800.0910 counseling content as required).
• Provide a written record of the contraceptive prescribed.
• If the pharmacist prescribes and dispenses under this subdivision, the pharmacist shall not prescribe a refill unless the patient has evidence of a clinical visit with a physician, PA, or APRN within the preceding three years.

High-yield trap: Treating subd. 14 like unlimited OTC birth-control handout authority without screening, age rules, or the three-year visit rule.

Subd. 15 — Nicotine Replacement Medications

• Authority: prescribe FDA-approved nicotine replacement medications under the Board protocol.
• Training: program specifically developed for prescribing NRT, then maintenance CE as Board specifies.
• Before prescribing: follow the standardized protocol; if appropriate, dispense NRT to the patient.
• Counsel + fact sheet (indications/contraindications, proper use, medical follow-up, Rule 6800.0910 content) + written record of the medication prescribed.
• No prescribing delegation; intern preparation allowed with authorized pharmacist review/approve/sign.

Exam note: Subd. 15 does not copy the contraceptive age/refill structure. Do not import the three-year visit rule into NRT items unless a stem invents a separate policy—the statute’s refill/clinical-visit gate is a subd. 14 feature.

Subd. 16 — Opiate Antagonists for Acute Overdose

• Authority: prescribe opiate antagonists for treatment of an acute opiate overdose.
• Training: program specifically developed for prescribing antagonists for acute overdose, plus maintenance CE.
• Protocol compliance, counseling, fact sheet, written record, and non-delegation rules mirror the structure of the other lanes.

Distinguish related authorities:

On the exam, identify whether the pharmacist is writing a prescription under subd. 16, operating under a therapy protocol, or relying on a public-access / standing-order pathway.

Subd. 17 — Drugs to Prevent Acquisition of HIV

• Pharmacists may prescribe and administer drugs to prevent acquisition of HIV in accordance with subd. 17.
• Board directed to develop a standardized protocol by January 1, 2025 (consultation with health advocacy groups and professional boards/associations as provided).
• Training specifically for prescribing HIV-prevention drugs; maintenance CE as Board specifies.
• Follow protocol before prescribing; if appropriate, dispense.
• Before dispensing a pharmacist-prescribed product, provide counseling and a fact sheet (indications/contraindications, method of use, medical follow-up, Rule 6800.0910 content).
• No delegation of prescribing; intern may prepare; authorized pharmacist must review, approve, and sign.

Related practice definition: §151.01, subd. 27, clauses (14) and (15) address prescribing/dispensing/administering HIV-prevention drugs and ordering/conducting/interpreting lab tests necessary for those therapies when subd. 17 requirements are met. Statute notes flag effective-date history for those practice-definition clauses—use current official text for exam timing, but know that HIV-prevention authority is a modern, protocol-bound expansion rather than historic general prescribing.

Subd. 18 — Treatment of Opioid Use Disorder (2026)

Effective in 2026, subd. 18 authorizes a pharmacist to prescribe, administer, and dispense legend drugs and Schedule III–V controlled substances to treat opioid use disorder only when the pharmacist determines under medically acceptable standards that treatment is indicated and necessary and documents the assessment, treatment, response, and monitoring in the patient's health record under an individual treatment plan.

Before prescribing, the pharmacist must complete the federal substance-use-disorder training described in 21 U.S.C. §823(m) and obtain the appropriate DEA registration when the drug is controlled. Before dispensing a pharmacist-prescribed drug, the pharmacist must counsel on proper use, follow-up, and applicable Rule 6800.0910 information. The prescribing authority cannot be delegated; an intern may prepare the prescription, but the authorized pharmacist must review, approve, and sign it. The subdivision does not bar protocol-based OUD therapy management or dispensing/administering a valid prescription from another practitioner.

Do not merge subd. 18 with subd. 16: subd. 16 covers acute-overdose antagonists under its Board protocol, while subd. 18 covers ongoing OUD treatment under a separate assessment, training, DEA, documentation, and counseling framework.

Practitioner Status for Limited Purposes

§151.01, subd. 23, as amended in 2026, provides that for specified sections “practitioner” also includes a pharmacist authorized to prescribe drug therapy under subd. 27 or §151.37. This remains a targeted definition for listed contexts, not a claim that pharmacists have unrestricted physician authority.

Study Checklist

1. Recite the five limited lanes: contraceptives, NRT, acute-overdose antagonists, HIV prevention, and OUD treatment.
2. For contraceptives: CDC MEC self-screening, 18+ or prior Rx if under 18, 3-year clinical visit before pharmacist-prescribed refill.
3. For subds. 14–17: know each protocol, training, counseling/fact-sheet, and nondelegation rule. For subd. 18: know individual treatment documentation, federal SUD training, DEA registration when prescribing controlled substances, counseling, and nondelegation.
4. Intern role: prepare only; authorized pharmacist reviews, approves, signs.
5. Separate subd. 16 prescribing from broader naloxone access statutes.
6. Do not treat §151.37 as a blank check: subd. 18 reaches only OUD treatment and only qualifying Schedule III–V controlled substances or legend drugs under its conditions.

Next: immunizations and vaccine administration under §151.01, subd. 27(6).